Skip to content

Study · Not a test of the peptide alone · 2025

27 results

A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies.

Daniel S, Waggett S, Lyles E, Sagut P, Shamaei Zadeh P, Marcelletti A, Stegura C, Wine Lee L

Journal of drugs in dermatology : JDD1 Apr 2025Cited by 13 (Europe PMC)

PMID40196945 (opens in a new tab)DOI10.36849/jdd.8605 (opens in a new tab)PepBankPUB-40196945
Publisher pagePubMedAsk about this study
Jump to 27 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study27

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone27

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Semaglutide aloneObservational studySafety outcome

    In a retrospective FDA adverse-event review, eczematous reactions were among the five most common cutaneous reactions associated with GLP-1 agonists including semaglutide.

    In plain wordsIn a reporting-system review, eczema-like reactions were among common skin reactions for GLP-1 medicines including semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableEczematous reactions
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneObservational studySafety outcome

    In a retrospective FDA adverse-event review, pruritus was among the five most common cutaneous reactions associated with GLP-1 agonists including semaglutide.

    In plain wordsIn a reporting-system review, itching was among common skin reactions for GLP-1 medicines including semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicablePruritus
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Semaglutide aloneObservational studySafety outcome

    In a retrospective FDA adverse-event review, drug eruptions were among the five most common cutaneous reactions associated with GLP-1 agonists including semaglutide.

    In plain wordsIn a reporting-system review, drug eruptions were among common skin reactions for GLP-1 medicines including semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableDrug eruptions
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 04HumanNot a test of Semaglutide aloneObservational studySafety outcome

    In a retrospective FDA adverse-event review, hyperhidrosis was among the five most common cutaneous reactions associated with GLP-1 agonists including semaglutide.

    In plain wordsIn a reporting-system review, excess sweating was among common skin reactions for GLP-1 medicines including semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableHyperhidrosis
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 05HumanNot a test of Semaglutide aloneObservational studySafety outcome

    In a retrospective FDA adverse-event review, alopecia was among the five most common cutaneous reactions associated with GLP-1 agonists including semaglutide.

    In plain wordsIn a reporting-system review, hair loss was among common skin reactions for GLP-1 medicines including semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableAlopecia
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  6. 06HumanNot a test of Semaglutide aloneObservational studySafety outcome

    In a retrospective FDA adverse-event review, life-threatening cutaneous adverse events accounted for 2.17% of all cutaneous reactions.

    In plain wordsIn a reporting-system review, life-threatening skin reactions were 2.17% of reported skin reactions.

    Peptide
    Semaglutide
    Outcome
    Not applicableLife-threatening cutaneous adverse events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound

    Measurements

    Proportion
    2.17%
    all cutaneous reactions

    Source sentences

    Summary
    Life-threatening cutaneous adverse events accounted for 2.17% of all cutaneous reactions,
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  7. 07HumanNot a test of Semaglutide aloneObservational studySafety outcome

    In the GLP-1 agonist class including semaglutide, type 2 diabetes use had higher alopecia reporting rates than weight-management use (P=0.000).

    In plain wordsFor GLP-1 medicines including semaglutide, type 2 diabetes use had more hair loss reports than weight-management use.

    Peptide
    Semaglutide
    Outcome
    IncreaseAlopecia rate by indication
    Study

    n: not reported in source

    Comparator
    Weight-management use
    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    It was also found that GLP-1 agonist use for T2DM exhibited significantly higher rates of alopecia (P=0.000) and hyperhidrosis (P=0.000) in comparison to use for weight management.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  8. 08HumanNot a test of Semaglutide aloneObservational studySafety outcome

    In the GLP-1 agonist class including semaglutide, type 2 diabetes use had higher hyperhidrosis reporting rates than weight-management use (P=0.000).

    In plain wordsFor GLP-1 medicines including semaglutide, type 2 diabetes use had more excess-sweating reports than weight-management use.

    Peptide
    Semaglutide
    Outcome
    IncreaseHyperhidrosis rate by indication
    Study

    n: not reported in source

    Comparator
    Weight-management use
    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    It was also found that GLP-1 agonist use for T2DM exhibited significantly higher rates of alopecia (P=0.000) and hyperhidrosis (P=0.000) in comparison to use for weight management.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  9. 09HumanNot a test of Liraglutide aloneObservational studySafety outcome

    In a retrospective FDA adverse-event review, eczematous reactions were among the five most common cutaneous reactions associated with GLP-1 agonists including liraglutide.

    In plain wordsIn a reporting-system review, eczema-like reactions were among common skin reactions for GLP-1 medicines including liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableEczematous reactions
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  10. 10HumanNot a test of Liraglutide aloneObservational studySafety outcome

    In a retrospective FDA adverse-event review, pruritus was among the five most common cutaneous reactions associated with GLP-1 agonists including liraglutide.

    In plain wordsIn a reporting-system review, itching was among common skin reactions for GLP-1 medicines including liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicablePruritus
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  11. 11HumanNot a test of Liraglutide aloneObservational studySafety outcome

    In a retrospective FDA adverse-event review, drug eruptions were among the five most common cutaneous reactions associated with GLP-1 agonists including liraglutide.

    In plain wordsIn a reporting-system review, drug eruptions were among common skin reactions for GLP-1 medicines including liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableDrug eruptions
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  12. 12HumanNot a test of Liraglutide aloneObservational studySafety outcome

    In a retrospective FDA adverse-event review, hyperhidrosis was among the five most common cutaneous reactions associated with GLP-1 agonists including liraglutide.

    In plain wordsIn a reporting-system review, excess sweating was among common skin reactions for GLP-1 medicines including liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableHyperhidrosis
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  13. 13HumanNot a test of Liraglutide aloneObservational studySafety outcome

    In a retrospective FDA adverse-event review, alopecia was among the five most common cutaneous reactions associated with GLP-1 agonists including liraglutide.

    In plain wordsIn a reporting-system review, hair loss was among common skin reactions for GLP-1 medicines including liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableAlopecia
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  14. 14HumanNot a test of Liraglutide aloneObservational studySafety outcome

    In a retrospective FDA adverse-event review, life-threatening cutaneous adverse events accounted for 2.17% of all cutaneous reactions.

    In plain wordsIn a reporting-system review, life-threatening skin reactions were 2.17% of reported skin reactions.

    Peptide
    Liraglutide
    Outcome
    Not applicableLife-threatening cutaneous adverse events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound

    Measurements

    Proportion
    2.17%
    all cutaneous reactions

    Source sentences

    Summary
    Life-threatening cutaneous adverse events accounted for 2.17% of all cutaneous reactions,
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  15. 15HumanNot a test of Liraglutide aloneObservational studySafety outcome

    In the GLP-1 agonist class including liraglutide, type 2 diabetes use had higher alopecia reporting rates than weight-management use (P=0.000).

    In plain wordsFor GLP-1 medicines including liraglutide, type 2 diabetes use had more hair loss reports than weight-management use.

    Peptide
    Liraglutide
    Outcome
    IncreaseAlopecia rate by indication
    Study

    n: not reported in source

    Comparator
    Weight-management use
    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    It was also found that GLP-1 agonist use for T2DM exhibited significantly higher rates of alopecia (P=0.000) and hyperhidrosis (P=0.000) in comparison to use for weight management.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  16. 16HumanNot a test of Liraglutide aloneObservational studySafety outcome

    In the GLP-1 agonist class including liraglutide, type 2 diabetes use had higher hyperhidrosis reporting rates than weight-management use (P=0.000).

    In plain wordsFor GLP-1 medicines including liraglutide, type 2 diabetes use had more excess-sweating reports than weight-management use.

    Peptide
    Liraglutide
    Outcome
    IncreaseHyperhidrosis rate by indication
    Study

    n: not reported in source

    Comparator
    Weight-management use
    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    It was also found that GLP-1 agonist use for T2DM exhibited significantly higher rates of alopecia (P=0.000) and hyperhidrosis (P=0.000) in comparison to use for weight management.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  17. 17HumanNot a test of Tirzepatide aloneObservational studySafety outcome

    In a retrospective FDA adverse-event review, eczematous reactions were among the five most common cutaneous reactions associated with GLP-1 agonists including tirzepatide.

    In plain wordsIn a reporting-system review, eczema-like reactions were among common skin reactions for GLP-1 medicines including tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    Not applicableEczematous reactions
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  18. 18HumanNot a test of Tirzepatide aloneObservational studySafety outcome

    In a retrospective FDA adverse-event review, pruritus was among the five most common cutaneous reactions associated with GLP-1 agonists including tirzepatide.

    In plain wordsIn a reporting-system review, itching was among common skin reactions for GLP-1 medicines including tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    Not applicablePruritus
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  19. 19HumanNot a test of Tirzepatide aloneObservational studySafety outcome

    In a retrospective FDA adverse-event review, drug eruptions were among the five most common cutaneous reactions associated with GLP-1 agonists including tirzepatide.

    In plain wordsIn a reporting-system review, drug eruptions were among common skin reactions for GLP-1 medicines including tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    Not applicableDrug eruptions
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  20. 20HumanNot a test of Tirzepatide aloneObservational studySafety outcome

    In a retrospective FDA adverse-event review, hyperhidrosis was among the five most common cutaneous reactions associated with GLP-1 agonists including tirzepatide.

    In plain wordsIn a reporting-system review, excess sweating was among common skin reactions for GLP-1 medicines including tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    Not applicableHyperhidrosis
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  21. 21HumanNot a test of Tirzepatide aloneObservational studySafety outcome

    In a retrospective FDA adverse-event review, alopecia was among the five most common cutaneous reactions associated with GLP-1 agonists including tirzepatide.

    In plain wordsIn a reporting-system review, hair loss was among common skin reactions for GLP-1 medicines including tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    Not applicableAlopecia
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  22. 22HumanNot a test of Tirzepatide aloneObservational studySafety outcome

    In a retrospective FDA adverse-event review, life-threatening cutaneous adverse events accounted for 2.17% of all cutaneous reactions.

    In plain wordsIn a reporting-system review, life-threatening skin reactions were 2.17% of reported skin reactions.

    Peptide
    Tirzepatide
    Outcome
    Not applicableLife-threatening cutaneous adverse events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Skin and wound

    Measurements

    Proportion
    2.17%
    all cutaneous reactions

    Source sentences

    Summary
    Life-threatening cutaneous adverse events accounted for 2.17% of all cutaneous reactions,
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  23. 23HumanNot a test of Tirzepatide aloneObservational studySafety outcome

    In the GLP-1 agonist class including tirzepatide, type 2 diabetes use had higher alopecia reporting rates than weight-management use (P=0.000).

    In plain wordsFor GLP-1 medicines including tirzepatide, type 2 diabetes use had more hair loss reports than weight-management use.

    Peptide
    Tirzepatide
    Outcome
    IncreaseAlopecia rate by indication
    Study

    n: not reported in source

    Comparator
    Weight-management use
    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    It was also found that GLP-1 agonist use for T2DM exhibited significantly higher rates of alopecia (P=0.000) and hyperhidrosis (P=0.000) in comparison to use for weight management.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  24. 24HumanNot a test of Tirzepatide aloneObservational studySafety outcome

    In the GLP-1 agonist class including tirzepatide, type 2 diabetes use had higher hyperhidrosis reporting rates than weight-management use (P=0.000).

    In plain wordsFor GLP-1 medicines including tirzepatide, type 2 diabetes use had more excess-sweating reports than weight-management use.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHyperhidrosis rate by indication
    Study

    n: not reported in source

    Comparator
    Weight-management use
    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    It was also found that GLP-1 agonist use for T2DM exhibited significantly higher rates of alopecia (P=0.000) and hyperhidrosis (P=0.000) in comparison to use for weight management.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  25. 25HumanNot a test of Semaglutide aloneObservational studySafety outcome

    In a retrospective FDA adverse-event review, there were no statistically significant differences in life-threatening cutaneous adverse events between GLP-1 agonist drug types including semaglutide.

    In plain wordsIn a reporting-system review, life-threatening skin-reaction reports did not differ significantly between GLP-1 drug types including semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeLife-threatening cutaneous adverse events by drug type
    Study

    n: not reported in source

    Comparator
    Other GLP-1 agonist drug types
    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    Life-threatening cutaneous adverse events accounted for 2.17% of all cutaneous reactions, with no statistically significant differences observed between drug types.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  26. 26HumanNot a test of Liraglutide aloneObservational studySafety outcome

    In a retrospective FDA adverse-event review, there were no statistically significant differences in life-threatening cutaneous adverse events between GLP-1 agonist drug types including liraglutide.

    In plain wordsIn a reporting-system review, life-threatening skin-reaction reports did not differ significantly between GLP-1 drug types including liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeLife-threatening cutaneous adverse events by drug type
    Study

    n: not reported in source

    Comparator
    Other GLP-1 agonist drug types
    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    Life-threatening cutaneous adverse events accounted for 2.17% of all cutaneous reactions, with no statistically significant differences observed between drug types.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  27. 27HumanNot a test of Tirzepatide aloneObservational studySafety outcome

    In a retrospective FDA adverse-event review, there were no statistically significant differences in life-threatening cutaneous adverse events between GLP-1 agonist drug types including tirzepatide.

    In plain wordsIn a reporting-system review, life-threatening skin-reaction reports did not differ significantly between GLP-1 drug types including tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeLife-threatening cutaneous adverse events by drug type
    Study

    n: not reported in source

    Comparator
    Other GLP-1 agonist drug types
    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    Life-threatening cutaneous adverse events accounted for 2.17% of all cutaneous reactions, with no statistically significant differences observed between drug types.
    1 context sentence
    Summary · context
    Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System,

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 5Current

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  2. Version 4

    12 Oct 2026, 11:11 UTC

    Study results updated

  3. Versions 2 to 3

    9 Oct 2026, 03:07 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.